Predict your next investment

Corporation
HEALTHCARE | Drug Discovery
mnemosynepharma.com

See what CB Insights has to offer

Stage

Series A - III | Alive

Total Raised

$12.95M

Valuation

$0000 

Last Raised

$1.3M | 7 yrs ago

About Mnemosyne Pharmaceuticals

Mnemosyne Pharmaceuticals is a drug discovery venture aiming to develop small molecule therapeutics to treat schizophrenia and other cognitive and neuropsychiatric disorders. The company is exploring additional indications including Alzheimer's disease, recovery from stroke and traumatic brain injury, and attention deficit/hyperactivity disorder (ADHD).

Mnemosyne Pharmaceuticals Headquarter Location

Three Davol Square Suite A425

Providence, Rhode Island, 02903,

United States

401-632-0383

Latest Mnemosyne Pharmaceuticals News

Slater Technology Fund-backed company to be acquired by Novartis

Dec 18, 2020

Slater Technology Fund-backed company to be acquired by Novartis By A SLATER TECHNOLOGY FUND-backed company, Cadent Therapeutics, has entered into an agreemnt to be acquired by Novartis in a deal worth up to $770 million. PROVIDENCE – The Cambridge, Mass.-based company Cadent Therapeutics has entered into an agreement to be acquired by Novartis in a deal worth up to $770 million, Slater Technology Fund announced Friday. The company was formed through a merger with the Slater Technology Fund-backed company Mnemosyne Pharmaceuticals. Mnemosyne developed a drug-discovery program targeting the creation of novel therapeutics to treat cognitive dysfunction and a broad range of central nervous system disorders. Slater, an evergreen not-for-profit seed fund dedicated to supporting new venture development in Rhode Island, invested $1.5 million in Mnemosyne, which became an ownership stake in Cadent. Slater noted that former Mnemosyne co-founder Frank Menniti has gone on to start MindImmunue Therapeutics, another Slater-backed company. Mnemosyne moved to Cambridge in 2015 as Luc Therapeutics after finishing an $11.5 million Series A financing round, and merged with Ataxion in 2017 to become Cadent. - Advertisement - “It is incredibly gratifying to see seed investments blossom in so many ways. Congratulations to [CEO of Cadent Therapeutics] Jodie Morrison and her team on creating such a great outcome for all, and to the Mnemosyne founders, who teamed with Richard Horan and Slater a decade ago,” said Thorne Sparkman, managing director of Slater. “This kind of success quite literally fuels the impact that entrepreneurs like the Mnemosyne founders can make by augmenting Slater’s evergreen investment in the next generation of ventures. We cannot wait to pay it forward.” Slater said the deal marked the fourth positive liquidity event for the fund in the past two years. Want to share this story? Click Here to purchase a link that allows anyone to read it on any device whether or not they are a subscriber. TAGS

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Mnemosyne Pharmaceuticals

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Mnemosyne Pharmaceuticals is included in 1 Expert Collection, including Biopharmaceuticals.

B

Biopharmaceuticals

5,882 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Mnemosyne Pharmaceuticals Patents

Mnemosyne Pharmaceuticals has filed 3 patents.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

9/26/2014

5/8/2018

NMDA receptor antagonists, Dissociative drugs, Piperidines, Amines, Amino acids

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

9/26/2014

00/00/0000

00/00/0000

Grant Date

5/8/2018

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Related Topics

NMDA receptor antagonists, Dissociative drugs, Piperidines, Amines, Amino acids

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.